Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer

Thyroid

Volumn 20, Issue 6, 2010, Pages 597-600

  Gkountouvas, Anastasios ^a   Kostoglou Athanassiou, Ifigeneia ^a   Veniou, Eirini ^a   Repousis, Panagiotis ^a   Ziras, Nikolaos ^a   Kaldrimidis, Philippos ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; SUNITINIB; ENZYME INHIBITOR; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CARCINOMA; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LYMPHOCYTOPENIA; MALE; MEGALOCYTOSIS; MONOCYTOPENIA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION INJURY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, MEDULLARY; CELL DIFFERENTIATION; CHEMICALLY INDUCED; DRUG EFFECTS; HEMATOPOIETIC SYSTEM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; THYROID NEOPLASMS;

ADULT; AGED; CARCINOMA, MEDULLARY; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FEMALE; HEMATOPOIETIC SYSTEM; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 77953944562     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0028     Document Type: Article

References (20)

1. Schlumberger M, Pacini F 2006 Thyroid Tumors, 3rd edition. É ditions Nucléon, Paris.
2. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648.
4. Kerbel RS 2008 Tumor angiogenesis. N Engl J Med 358: 2039-2049.
5. Hoffbrand AV, Catovsky D, Tuddenham EGD 2005 Postgraduate Haematology, 5th ed. Blackwell Publishing Ltd., Malden, MA.
6. Up To Date, Inc. 2009, NIH grading of hematologic toxicity. Available at http://uptodateinc.com/online/content/image .do?imageKey=hema-pix/hematolo.htm. Accessed November 17, 2009.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
8. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
9. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M 2007 New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32.
10. Krause DS, Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
11. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499.
12. Sherman SI 2009 Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23:713-722.
13. Woyach JA, Shah MH 2009 New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 16:715-731.
14. HongMH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY 2009 Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41:67-72.
15. Schwandt A, Wood LS, Rini B, Dreicer R 2009 Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Oncol Targets Ther 2:51-61.
16. Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM 2008 Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113: 1309-1314.
17. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL III, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE 2008 Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:6025 (abstract).
18. Goulart B, Carr L, Martins RG, Eaton K, Kell E, Wallace S, Capell P, Mankoff D 2008 Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). J Clin Oncol 26:6062 (abstract).
19. Ravaud A, De la Fouchardière C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, Bournaud C, Delord J, Weryha G, Catargi B 2008 Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26:6058 (abstract).
20. Van Nostrand D 2009 The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 19:1381-1391.